Medication Metabolism

The CYP450 enzyme family (particularly CYP2C19, CYP2D6, CYP2C9, and CYP3A4) handles the clearance of roughly half of all commonly prescribed medications. Each enzyme has its own variant set and its own phenotypic spectrum from "poor" to "ultrarapid" metabolizer. The combination across enzymes shapes an individual's overall pharmacogenomic profile.

Carriers of CYP2C19 reduced-activity variants are associated with poor activation of clopidogrel (Plavix) and longer exposure to PPIs and certain antidepressants. CYP2D6 phenotype shifts response to opioids, beta-blockers, and many psychiatric medications. CYP2C9 variants shape warfarin dosing alongside VKORC1. Each variant is consequential; the combination is more so.

Drug-drug interactions through these enzymes are extensive and often unpredictable without knowing the genotype. Grapefruit juice, St. John's wort, smoking, and many over-the-counter supplements all shift CYP activity. Liver function, age, and acute illness produce further variability.

The "this medication didn't work for me" or "I had a strong reaction at a low dose" pattern often tracks to a CYP variant the prescriber didn't have visibility into. Which combination you carry is information worth providing to clinicians, particularly before starting any psychiatric medication, anticoagulant, or anti-platelet drug.